

---

1 **Novel pectin from crude polysaccharide of *Syzygium aromaticum* against SARS-**  
2 **CoV-2 activities by targeting 3CLpro**

3 Can Jin<sup>1,2,4#</sup>, Bo Feng<sup>3,4#</sup>, Rongjuan Pei<sup>5#</sup>, Yaqi Ding<sup>2,4</sup>, Meixia Li<sup>2,4</sup>, Xia Chen<sup>2,4</sup>, Zhenyun Du<sup>2,4</sup>,  
4 Yangxiao Ding<sup>8</sup>, Chunfan Huang<sup>1,2,4</sup>, Bo Zhang<sup>5</sup>, Xinwen Chen<sup>5\*</sup>, Yi Zang<sup>3,4\*</sup>, Jia Li<sup>3,4\*</sup>, Kan Ding<sup>1,2,4,6,7\*</sup>

5 <sup>1</sup>*College of Pharmacy, Nanjing University of Chinese Medicine, 138 Xianlin Avenue, Nanjing, Jiangsu*  
6 *Province 210029, China*

7 <sup>2</sup>*Glycochemistry and Glycobiology Lab, Key Laboratory of Receptor Research*

8 <sup>3</sup>*National Center for Drug Screening, State Key Laboratory of Drug Research, Shanghai Institute of*  
9 *Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, P. R. of*  
10 *China*

11 <sup>4</sup>*University of Chinese Academy of Science, No.19A Yuquan Road, Beijing 100049, P. R. China*

12 <sup>5</sup>*State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science,*  
13 *Chinese Academy of Sciences, Wuhan, 430071, China*

14 <sup>6</sup>*Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of*  
15 *Science. SSIP Healthcare and Medicine Demonstration Zone, Zhongshan Tsuihang New District,*  
16 *Zhongshan, Guangdong, China, 528400*

17 <sup>7</sup>*Henan Polysaccharide Research Center, Academy of Chinese Medical Sciences, Henan University of*  
18 *Chinese Medicine, Zhengzhou 450046, Henan, China*

19 <sup>8</sup>*Shanghai High School International Division, No.989, Baise Road, Shanghai, China, 200231*

20 <sup>#</sup>These authors contributed equally

21 <sup>\*</sup>Corresponding authors

22 Corresponding address: Glycochemistry and Glycobiology Lab, Shanghai Institute of Materia  
23 Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Pudong, Shanghai 201203,  
24 P.R. of China

25 Kan Ding, E-mail: [dingkan@simmm.ac.cn](mailto:dingkan@simmm.ac.cn)

26

27

28 **Abstract**

29 To date, COVID-19 is still a severe threat to public health, hence specific effective therapeutic  
30 drugs development against SARS-CoV-2 is urgent needed. 3CLpro and PLpro and RdRp are  
31 the enzymes required for the SARS-CoV-2 RNA synthesis. Therefore, binding to the enzyme  
32 may interfere the enzyme function. Before, we found that sulfated polysaccharide binding to  
33 3CLpro might block the virus replication. Hence, we hypothesize that negative charged pectin  
34 glycan may also impede the virus replication. Here we show that 922 crude polysaccharide  
35 from *Syzygium aromaticum* may near completely block SARS-CoV-2 replication. The  
36 inhibition rate was 99.9% (EC<sub>50</sub> : 0.90 μM). Interestingly, 922 can associates with 3CLpro,  
37 PLpro and RdRp. We further show that the homogeneous glycan 922211 from 922 may  
38 specifically attenuate 3CL protease activity. The IC<sub>50</sub>s of 922 and 922211 against 3CLpro are  
39 4.73 ± 1.05 μM and 0.18 ± 0.01 μM, respectively. Monosaccharide composition analysis  
40 reveals that 922211 with molecular weight of 78.7 kDa is composed of rhamnose, galacturonic  
41 acid, galactose and arabinose in the molar ratio of 8.21 : 37.81 : 3.58 : 4.49. The structure  
42 characterization demonstrated that 922211 is a homogalacturonan linked to RG-I pectin  
43 polysaccharide. The linear homogalacturonan part in the backbone may be partly methyl  
44 esterified while RG-I type part bearing 1, 4-linked α-GalpA, 1, 4-linked α-GalpAOMe and 1,  
45 2, 4-linked α-Rhap. There are four branches attached to C-1 or C4 position of Rhamnose  
46 glycosyl residues on the backbone. The branches are composed of 1, 3-linked β-Galp, terminal  
47 (T)-linked β-Galp, 1, 5-linked α-Araf, T-linked α-Araf, 4-linked α-GalpA and/or 4-linked β-  
48 GalpA. The above results suggest that 922 and 922211 might be a potential novel leading  
49 compound for anti-SARS-CoV-2 new drug development.

50 **Keywords:**

51 *COVID-19; SARS-CoV-2; 3CL protease; PLpro; RdRp; Syzygium aromaticum; Polysaccharide;*  
52 *Pectin*

53

54 **1. Introduction**

55 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is kind of novel  
56 coronavirus. It made a serious life-threatening disease Coronavirus Disease 2019 (COVID-19).  
57 The first case of COVID-19 was reported by the World Health Organization (WHO) on  
58 December 31, 2019 (Majumder & Minko, 2021). Owing to SARS-CoV-2 infection spreading  
59 rapidly and a shortage of specific treatments for COVID-19, it has made an ongoing pandemic  
60 in a growing number of countries, which has caused a serious public health threat (Laventhal  
61 et al., 2020). On March 11, 2020, WHO declared COVID-19 as a global pandemic (Cucinotta  
62 & Vanelli, 2020). Up to now, the virus pandemic in more than 200 countries has resulted in  
63 major loss of human life globally. As of October 19, 2021, more than 240 million people were  
64 infected with the COVID-19 disease and 4.9 million deaths have been reported globally and  
65 the number is increasing rapidly (<https://covid19.who.int/>). Since the outbreak of COVID-19,  
66 a mass of studies have attempted to reveal the structural characteristics of SARS-CoV-2 and its  
67 infection mechanism. Some investigations found that SARS-CoV-2 is an enveloped virus  
68 consisting of a positive-sense, single-stranded RNA genome of around 30 kb (Asselah et al.,  
69 2021). The envelope is covered with glycoprotein spikes. SARS-CoV-2 viral genome encoded  
70 its structural proteins namely, spike (S) surface glycoprotein, membrane (M) protein, envelope  
71 (E) protein, and nucleocapsid (N) protein and nonstructural proteins (RNA polymerase, RdRp;

72 papain-like protease, PLpro; coronavirus main protease, 3CLpro) (Yadav et al., 2021). SARS-  
73 CoV-2 and SARS-CoV are highly similar genetically and at the protein production level  
74 (Hatmal et al., 2020). Almost 85% homology of this virus is similar to the SARS-CoV  
75 (Petrosillo et al., 2020). Similar to SARS-CoV, the S1 protein on the surface of the SARS-CoV-  
76 2 binds to ACE2 on the plasma membrane of infected cells, initiating receptor-mediated  
77 endocytosis (Yeung et al., 2021). Similarly, in the SARS-CoV-2 replication cycle, viral  
78 proteinases 3CLpro and PLpro cleave viral polyproteins into effector proteins to ensure normal  
79 replication (Moustaqil et al., 2021). As early as the study of coronavirus, scientists found that  
80 3CL and PLpro proteins were attractive target molecules for the treatment of coronavirus,  
81 because they are key enzymes in the process of virus replication (Báez-Santos et al., 2015).  
82 These mechanisms suggest that the development of anti-COVID-19 drugs and vaccines induced  
83 antibody can inhibit the binding of S1 protein to host cell ACE2 and target 3CL and PLpro  
84 proteins (Arvin et al., 2020; Yan & Gao, 2021). While the best interventions to control and  
85 ultimately stop the pandemic are prophylactic vaccines, antiviral therapeutics are important to  
86 limit morbidity and mortality in those already infected (Froggatt et al., 2020). Through  
87 structure-assisted drug design, virtual drug screening and high-throughput screening, scientists  
88 found that natural and synthetic active substances had the potential to become the lead  
89 compounds for the new drug development for the treatment of COVID-19. It is noteworthy that  
90 some natural small molecules, such as flavonoids can target 3CL and PLpro proteins (Russo et  
91 al., 2020) and inhibit the binding of S1 and ACE2 (Mouffouk et al., 2021). They inhibit the  
92 replication of SARS-CoV-2 in Vero E6 cells (Muchtaridi et al., 2020). Because of its non-toxic  
93 and multi-target characteristics, macromolecules polysaccharides have attracted the attention

94 of scientists in the treatment of various diseases (Kocabiyik et al., 2021). In fact, scientists  
95 have also explored that polysaccharides have good anti-SARS-CoV-2 effects, such as heparin,  
96 some seaweed polysaccharides, and sulfated derivatives of chitosan (Chen et al., 2020; Modak  
97 et al., 2021; Pereira & Critchley, 2020; Tandon et al., 2021). The similarity of these  
98 polysaccharides is that they contain a large amount of sulfate ions. Likewise, it was reported  
99 that Heparin blocked SARS-CoV-2 binding and infection in mechanism of negatively charged  
100 sulfate and carboxyl groups in Heparin stabilizing the association with several positively  
101 charged amino acid residues of Spike (Hu et al., 2021). Hence, we hypothesize that natural  
102 pectin polysaccharides also with negative charged with a mass of carboxyl groups might also  
103 effectively inhibit SARS-CoV-2. To address, flowers of the traditional Chinese medicine  
104 *Syzygium aromaticum* L. were selected firstly as the source of pectin polysaccharides extraction  
105 in this study. *Syzygium aromaticum* belongs to the genus Eupatorium. Actually, flower buds and  
106 fruits of *Syzygium aromaticum* is often employed as medicine for diseases treatment in China  
107 and Southeast Asia. Ancient medical books and modern pharmacological studies have shown  
108 that *Syzygium aromaticum* has strong catharsis, insecticidal and bacteriostatic effects (Batiha et  
109 al., 2019, 2020; Radünz et al., 2019). However, studies have shown that these biological  
110 activities often arise from small molecules in *Syzygium aromaticum*, such as eugenol, volatile  
111 oil, etc. In this paper, we firstly extracted and isolated polysaccharide 922 from *Syzygium*  
112 *aromaticum*. Then we test the bioactivity of the polysaccharide against SARS-CoV-2 activity.  
113 Further, one homogeneous polysaccharide 922211 was purified from 922 followed by 3CPpro,  
114 PLpro and RdRp enzymes activities measurement using this polysaccharide and its native one.  
115 Then we characterized the structure of one homogeneous polysaccharide 922211 using the

---

116 method combining chemical and spectral analysis, including methylation analysis, partial acid  
117 hydrolysis, GC-MS (Gas chromatography-mass spectrometry) and nuclear magnetic resonance  
118 (NMR) spectroscopy.

119

## 120 **2. Experimental**

### 121 *2.1. Materials and reagents*

122 Dried flower buds of *Syzygium aromaticum*. were purchased from Bozhou Decoction  
123 Pieces and Medicinal Materials Factory (Bozhou, Anhui Province, China). DEAE Sepharose  
124 Fast Flow and Sephacryl S-300 HR was obtained from GE healthcare (Danderyd, Sweden,  
125 USA). CMC (1-Cyclo-hexyl-3- (2-morpholinoethyl) carbodiimide metho-p-toluenesulfonate)  
126 and Iodomethane were purchased from TCI (Tokyo, Japan). T-series Dextrans were obtained  
127 from Amersham Pharmacia Biotech (Little Chalfont, Buckinghamshire, UK). Standard  
128 monosaccharides were bought from Shanghai Macleans Biochemical Technology Co., Ltd.  
129 (Shanghai, China). BCA kit was obtained from Shanghai biyuntian Biotechnology Co., Ltd  
130 (Shanghai, China). Other reagents were analytical grade and from Sinopharm Chemical  
131 Reagent Co. Ltd. (Shanghai, China).

### 132 *2.2. Extraction, isolation and purification of polysaccharides*

133 The crude polysaccharide was extracted through water extraction and alcohol precipitation.  
134 In brief, the dried flower buds of *Syzygium aromaticum* was immersed (solid-liquid ratio : 1  
135 kg/15 L) in water for 12 h. The soaked mixture was extracted with boiling water for 2 h, twice  
136 in total. The combined supernatant was concentrated, dialyzed (dialysis membrane for small  
137 molecule), concentrated, centrifuged and precipitated with three volumes of 95% EtOH. The

---

138 crude polysaccharide 922 (8 g) was dissolved in 100 mL distilled water and centrifuged (4000  
139 g, 10 min/time). The supernatant was fractionated by anion-exchange chromatography on  
140 DEAE-cellulose column ( $\text{Cl}^-$ , 50 cm  $\times$  5 cm), eluted stepwise with distilled water, 0.05, 0.1, 0.2  
141 and 0.4 M NaCl solution. For the sample solution collected by each mobile phase, two curves  
142 need to be drawn. One is the polysaccharide elution curve detected by phenol-sulfuric acid  
143 method and the other is the protein curve determined by BCA kit. Hence, based on the curves,  
144 the corresponding polysaccharide and protein from one elution would be accumulated. The  
145 Elution processes was shown in **Fig. 6F**. Among them, the fraction eluted with 0.2 M NaCl  
146 elution was collected, concentrated and lyophilized to obtain polysaccharide 9222.  
147 Subsequently, 9222 (200 mg) was dissolved in 5 mL distilled water and centrifuged (4000 g,  
148 10 min/time). The supernatant was further purified by gel permeation chromatography using  
149 Sephacryl S-300 column (100 cm  $\times$  2.6 cm) and the Sephacryl S-100 column (100 cm  $\times$  2.6  
150 cm), by which was eluted with 0.2 M NaCl to achieve the target polysaccharide 922211. The  
151 relative molecular weight of 922211 was estimated by high performance gel permeation  
152 chromatography (HPGPC) with series-connected Shodex SUGAR KS-804 and Shodex  
153 SUGAR KS-802 columns.

### 154 2.3. Homogeneity and molecular weight determination

155 Determining the homogeneity and molecular weight of polysaccharides were measured by  
156 high performance gel permeation chromatography (HPGPC) on an Agilent 1260 HPLC system  
157 equipped with series-connected Shodex SUGAR KS-804 and Shodex SUGAR KS-802  
158 columns, with 0.1 M  $\text{NaNO}_3$  used as the mobile phase at a flow rate of 0.5 mL/min (Cong et  
159 al., 2014). All samples were prepared as 4 mg/mL in mobile phase, and 10  $\mu\text{L}$  of solution was

160 injected in each run (60 min for each run). The eluate was monitored with an RI (Keep in 25 °C)  
161 and a UV detector, and the column temperature was kept at 35 °C.

#### 162 2.4. *Monosaccharide composition analysis*

163 The monosaccharide composition was analyzed using PMP pre-column derivatization  
164 based on the previous reported (J. Dai et al., 2010). In briefly, 922211 (2 mg) was hydrolyzed  
165 with 4 mL of 2 M TFA (trifluoroacetic acid), followed by PMP derivation. 10 µL of the  
166 derivative solution was analyzed by high performance liquid chromatography (HPLC) to  
167 understand the sugar composition.

#### 168 2.5. *NMR analysis*

169 For NMR analysis, 922211 (30 mg) was deuterium-exchanged and dissolved by 0.5 mL  
170 D<sub>2</sub>O (99.8% D), and then lyophilized and redissolved in 0.5 mL D<sub>2</sub>O (99.8% D). The <sup>1</sup>H, <sup>13</sup>C  
171 NMR and 2D NMR spectra (COSY, HSQC and HMBC) were measured at 25 °C with acetone  
172 as internal standard ( $\delta\text{H} = 2.29$ ,  $\delta\text{C} = 31.5$ ). NMR spectra were recorded on a Bruker AVANCE  
173 III NMR spectrometer.

#### 174 2.6. *Methylation analysis*

175 The dried polysaccharide (10 mg) was methylated for 3-4 times based on previous  
176 methods (HAKOMORI, 1964). The methylated polysaccharide was hydrolyzed and then  
177 reduced with sodium borohydride and acetylated. The partially methylated alditol acetates were  
178 examined by gas chromatography–mass spectrometry (GC-MS). Mass spectra of the  
179 derivatives were analyzed using Complex Carbohydrate Structural Database of Complex  
180 Carbohydrate Research Centre (<http://www.ccrcc.uga.edu/>).

181



182 2.7. *Uronic acid reduction*

183 The approach of uronic acid reduction was based on the reported method (Taylor & Conrad,  
184 1972). In brief, 40 mg polysaccharide was dissolved in 40 mL H<sub>2</sub>O. CMC (600 mg) was added  
185 and pH was kept at 4.75 with 0.01 M HCl for 2 h. Then 2 M fresh aqueous sodium borohydride  
186 (16 mL) was added slowly to the mixture (Sodium borohydride solution shall be added within  
187 30-60 min) and maintained pH at 7 with 4 M HCl for 2 h at room temperature. The mixture was  
188 dialyzed (1,000 mL × 4) for 24 h at room temperature. Then the retentate was lyophilized to  
189 achieve carboxyl reduced polysaccharide, followed by monosaccharide composition and  
190 glycosyl residues analyses.

191 2.8. *Enzymatic activity and inhibition assays*

192 The enzyme activity and inhibition assays of SARS-CoV-2 3CL<sup>pro</sup> have been described  
193 previously (W. Dai et al., 2020; Jin et al., 2020). Briefly, the recombinant SARS-CoV-2 3CL<sup>pro</sup>  
194 (40 nM at a final concentration) was mixed with each compound in 50 μL assay buffer (20 mM  
195 Tris, pH7.3, 150 mM NaCl, 1mM EDTA, 1% Glycerol, 0.01% Tween-20) and incubated for 10  
196 min. The reaction was initiated by adding the fluorogenic substrate MCA-AVLQSGFRK (DNP)  
197 K (GL Biochem, Shanghai), with a final concentration of 20 μM. After that, the fluorescence  
198 signal at 320 nm (excitation)/405 nm (emission) was immediately measured by continuous 8  
199 points for 8 min with an EnVision multimode plate reader (Perkin Elmer, USA). The initial  
200 velocity was measured when the protease reaction was proceeding in a linear fashion.

201 The activity of SARS-CoV-2 PL<sup>pro</sup> was also measured by a continuous 8 points  
202 fluorometric assay for 8 min. Briefly, the recombinant SARS-CoV-2 PL<sup>pro</sup> (40 nM at a final  
203 concentration) was mixed with each compound in 50 μL assay buffer (20 mM Tris pH 8.0, 0.01%

204 Tween 20, 0.5 mM DTT) and incubated for 10 min. The reaction was initiated by adding the  
205 substrate Z-RLRGG-AMC (GL Biochem, Shanghai) with a final concentration of 50  $\mu$ M, using  
206 wavelengths of 355 nm and 460 nm for excitation and emission, measured by an EnVision  
207 multimode plate reader (Perkin Elmer, USA).

208 The detection of RNA synthesis by SARS-CoV-2 RdRp complex were established based  
209 on a real-time assay with the QuantiFluor® dsDNA Dye (Promega), which contains a  
210 fluorescent DNA-binding dye that enables sensitive quantitation of small amounts of double-  
211 stranded DNA (dsDNA) in solution. The fluorescence was measured using wavelengths of 504  
212 nm and 531 nm for excitation and emission, measured by an EnVision multimode plate reader  
213 (Perkin Elmer, USA). The assay records the synthesis of dsRNA in a reaction using a poly-U  
214 molecule as a template and ATP as the nucleotide substrate. Reactions were performed in  
215 individual wells of white 384-well low volume round bottom plates. The standard reaction  
216 contained 50 mM Tris-HCl, pH 7.5, 50 mM Ammonium acetate, 0.5 mM MnCl<sub>2</sub>, 20  $\mu$ M ATP,  
217 0.2  $\mu$ M poly-U template–primer RNA, 0.01% Tween-20

## 218 2.9. ELISA

219 10  $\mu$ g/mL ACE2 coating buffer were used to treat the 96 well plate at 4 °C overnight  
220 following with 200  $\mu$ L washing buffer for three times. Then the 96-well plate was blocked by  
221 2% BSA at room temperature for 2 h. After that, 100  $\mu$ L biotinylated S1 protein was added and  
222 incubated at room temperature. At the same time, the positive control and the negative control  
223 were set. After incubation for 1 h, the plate was washed for three times and each time for 5 min.  
224 Subsequently, 100  $\mu$ L Streptavidin-HRP was added to final concentration of 200 ng/mL at room  
225 temperature and incubated for 1 h. After incubation for 1 h, the plate was washed for three times.

---

226 Then, 100  $\mu$ L TMB were added and incubated in the dark for 35 min. Finally, 50  $\mu$ L stop  
227 solution were added to stop the reaction followed by detection at 450 nm by microplate reader  
228 (BioTek).

### 229 *2.10. Antiviral test in vitro*

230 The experiments related to SARS-CoV-2 are completed at National Biosafety Laboratory,  
231 Wuhan, Chinese Academy of Sciences.

232 SARS-CoV-2 (WIV04) was passaged in Vero E6 cells and tittered by plaque assay. Vero  
233 E6 cells were treated with polysaccharides or positive control at indicated concentration and  
234 infected by SARS-CoV-2 virus at MOI 0.01. After 24 h incubation at 37 °C, supernatants were  
235 collected and the viral RNAs were extracted by Magnetic Beads Virus RNA Extraction Kit  
236 (Shanghai Finegene Biotech, FG438), and quantified by real-time RT-PCR with Taqman probe  
237 targeting to the RBD region of S gene.

## 238 **3. Results and discussion**

### 239 *3.1. Purity, Molecular weight and monosaccharide composition analysis of 922211*

240 The crude polysaccharide 922 was achieved at a yield of 4.2% (42 g/kg) by water  
241 extraction. 922 was further fractioned by DEAE Sepharose™ Fast Flow to obtain 9222  
242 component (386.4 mg/8 g, yield is 4.83%) from the 0.2 M NaCl eluent. 9222 was further  
243 purified through gel permeation chromatography to achieve polysaccharide 922211  
244 (61.28mg/200 mg, yield is 30.64%). Polysaccharide 922211 homogeneity was estimated by  
245 HPGPC, in which it showed one symmetrical peak. The relative molecular weight of 922211  
246 was estimated to be 78.7 kDa. Monosaccharide composition analysis showed that 922211 was  
247 composed of rhamnose, galacturonic acid, galactose and arabinose in the molar ratio of 8.21 :

248 37.81 : 3.58 : 4.49 (**Table 1**).

249 Table 1. Monosaccharide composition of 922211, its hydrolysate, and reduced derivatives.

Monosaccharides	Molar ratios (%)			
	922211	R3922211	P2922211I	R3P2922211I
Rha	8.21	15.05	5.30	1.96
GalA	37.81	nd	47.07	nd
Gal	3.58	64.91	trace	49.89
Ara	4.49	8.87	nd	nd

250 nd: not detected.

### 251 3.2 Linkage pattern analysis

252 To determine the glycosyl linkage type, 922211 was methylated, hydrolyzed, reduced and  
253 acetylated to produce the partially methylated alditol acetates (PMAA), which was analyzed by  
254 gas chromatography-mass spectrometry (GC-MS) (**Table 2**). For 922211, the linkage pattern  
255 of the galactose residues included 1, 3-linked Gal (7.81%) and Terminal (T)-linked Gal  
256 (12.67%). The arabinose residues in the 922211 were consisted of Terminal (T)-linked Ara  
257 (16.46%) and 1, 5-linked Ara (4.80%). The rhamnose residues contained 1, 2, 4-linked Rha  
258 (19.07%). 922211 had a mass of galacturonic acid (**Table 1**), which could not be methylated  
259 successfully. Hence, the carboxyl group of galacturonic acid needs to be reduced to hydroxyl  
260 to acetylate and produce the PMAA successfully to then analyze the linkage type of  
261 galacturonic acid in 922211. Noticeably, a new linkage style 1, 4-linked Gal (37.91%) appeared  
262 in reduced polysaccharide R3922211 after being methylated. Combined with the  
263 monosaccharide composition analysis of 922211 (galacturonic acid 37.81%), it could be  
264 inferred that the galacturonic acid residues of 922211 is 1, 4-linked GalA.

265

266

267 Table. 2. Linkage styles of 922211 and its hydrolyzed and reduced derivatives.

Glycosidic linkage	Molar ratios (%)			
	922211	R3922211	P2922211I	R3P2922211I
T-Ara	16.46	2.45	<i>nd</i>	<i>nd</i>
1,5-Ara	4.80	1.04	<i>nd</i>	<i>nd</i>
1,2-Rha	<i>nd</i>	<i>nd</i>	30.07	2.82
1,2,4-Rha	19.07	6.40	16.86	<i>nd</i>
1,4-Gal	<i>nd</i>	37.91	<i>nd</i>	47.12
T-Gal	12.67	4.08	12.79	2.19
1,3-Gal	7.81	1.87	<i>nd</i>	<i>nd</i>

268 *nd: not detected.*

### 269 3.3. Partial acid hydrolysis

270 To elucidate the detail structure features of the backbone and branches of the  
271 polysaccharide, 922211 was subjected firstly to partial acid hydrolysis, followed by dialysis  
272 against de-ionized water. The intra-dialysate P2922211I (108 mg, yield: 72%) was obtained.  
273 Then the homogeneity of P2922211I was analyzed by HPGPC and identified to be a  
274 homogenous fraction with an average molecular weight of 41.4 kDa. Monosaccharide  
275 composition analysis revealed that P2922211I was composed of Rha and GalA in  
276 approximately molar ratio of 5.30 : 47.07. Comparing with 922211, the relative amount of  
277 galacturonic acid in P2922211I increased while the relative amount of galactose and arabinose  
278 disappeared, indicating that galactose and arabinose might locate in the side chains.  
279 Methylation analysis results suggested that P2922211I was composed of T-linked Gal (12.79%),  
280 1, 2-linked Rha (30.07%) and 1, 2, 4-linked Rha (16.86%). Since P2922211I was acid  
281 polysaccharide, to make sure where the carboxyl group came from why residue, this  
282 polysaccharide was reduced to obtain R3P2922211I. Comparing the amount of sugar residues  
283 of P2922211I and R3P2922211I, we found that a new linkage style 1, 4-linked Gal (47.12%)

284 appeared. This result helped to deduce that the galacturonic acid residue of P2922211I was 1,  
285 4-linked GalA.

286 Since sugar composition analysis indicated that P2922211I contained Rha and GalA in the  
287 ratio of 5.30 : 47.07, while the methylation results show the residues linkage type of this fraction  
288 has 1,2-linked (30.07%), 1,2,4-linked (16.86) and T-Gal (12.79) without any GalA linkage type  
289 due to the methylation method defect. However, after the reduction, the methylation results  
290 demonstrated that R3P2922211I had 1,4-linked Gal (47.12%) represented GalA as dominant  
291 part in the P2922211I and trace 1,2-linked Rha (2.82) and T-Gal (2.19). The above results  
292 suggested that backbone of 922211 somehow might contain homogalacturonan region of pectin  
293 at least in P2922211I fraction. The branched chains were composed of T-, 1, 3-linked Gal and  
294 T-, 1, 5-linked Ara. This inference was further evidenced by 1D and 2D NMR data analysis as  
295 followed.

#### 296 *3.4. NMR spectral analysis*

297 The <sup>13</sup>C (**Fig. 1A, C**) and <sup>1</sup>H (**Fig. 1B**) NMR spectra were assigned and depicted in **Table**  
298 **3** supported by the monosaccharide composition, methylation analysis, partial acid hydrolysis,  
299 two-dimension NMR spectra of 922211 and P2922211I (**Fig. 2**).

300

301

302

303

304

305

306 Table. 3.  $^1\text{H}$  and  $^{13}\text{C}$  NMR chemical shifts (ppm) assignments for major signals of 922211.

Sugar residues	Chemical shifts ( $\delta$ , ppm)							Reference
	1	2	3	4	5	6	-OCH <sub>3</sub>	
<b>a</b> $\alpha$ -Araf(1 $\rightarrow$	H	5.28	4.06/4.10	3.98	4.20	3.9	5.28	(Lin et al., 2016)
	C	108.18	85.29	77.61	83.07	62.38	108.18	(Zheng et al., 2015)
<b>b</b> $\rightarrow$ 5)- $\alpha$ -Araf(1 $\rightarrow$	H	5.17	4.23	40.8	4.12	3.98	5.17	(Lin et al., 2016)
	C	108.61	82.31	74.86	85.36	69.84	—	(Zheng et al., 2015)
<b>c</b> $\rightarrow$ 2,4)- $\alpha$ -Rhap(1 $\rightarrow$	H	5.15	4.20	4.10	4.09	3.96	1.33	(Dong et al., 2010)
	C	100.25	78.97	74.85	78.89	71.45	17.75	
<b>d</b> $\rightarrow$ 4)- $\alpha$ -GalpA(1 $\rightarrow$	H	5.15	3.82	4.08	4.52	5.03	—	(Petersen et al., 2008;
	C	100.85	69.11	74.86	79.89	71.83	174.78	Shakhmatov et al., 2015)
<b>d'</b> $\rightarrow$ 4)- $\alpha$ -GalpA(1 $\rightarrow$	H	5.15	3.85	4.09	4.52	5.01	—	(Golovchenko et al., 2007;
	C	101.08	69.22	74.86	79.44	71.94	174.34	Petersen et al., 2008)
<b>e</b> $\rightarrow$ 4)- $\alpha$ -6MeGalpA(1 $\rightarrow$	H	5.01	3.76	4.01	4.39	5.08	—	3.87 (Shakhmatov et al., 2015)
	C	101.67	71.81	69.56	83.3	72.57	172	54.20
<b>e'</b> $\rightarrow$ 4)- $\alpha$ -6MeGalpA(1 $\rightarrow$	H	5.01	3.81	4.04	4.49	5.02	—	3.81 (Petersen et al., 2008)
	C	101.47	71.81	69.56	83.3	72.95	172.05	54.13
<b>f</b> $\rightarrow$ 3)- $\beta$ -Galp(1 $\rightarrow$	H	4.70	3.56	3.76	4.06	3.98	3.86	(Liu et al., 2018)
	C	104.67	72.54	80.27	70.54	73.87	62.43	
<b>g</b> $\beta$ -Galp(1 $\rightarrow$	H	4.70	3.59	3.75	4.07	3.76	3.81	(Li et al., 2018; Liu et al.,
	C	104.67	71.81	70.87	70.61	72.95	62.18	2018)
<b>h</b> $\rightarrow$ 4)- $\alpha$ -GalpA	H	5.4	3.88/3.92	4.05	4.53	5.15	—	(Petersen et al., 2008)
	C	93.52	69.83	70.16	79.29	71.93	174.75	
<b>i</b> $\rightarrow$ 4)- $\beta$ -GalpA	H	4.71	3.56/3.59	3.84	4.47	5.1	—	(Petersen et al., 2008)
	C	97.49	72.43/72.48	72.24	78.74	73.05	174.34	


307 In  $^{13}\text{C}$  NMR spectrum, the two intense anomeric signals at  $\delta$  100.85 and  $\delta$  101.08 could be  
308 assigned to C-1 of 1, 4-linked  $\alpha$ -GalpA (**d**, **d'**) in different chemical environments, respectively.  
309 Signals at  $\delta$  101.47 and  $\delta$  101.67 could be assigned to C-1 of 1, 4-linked  $\alpha$ -6MeGalpA (**e'**, **e**)  
310 in different chemical environments, respectively. Indeed, the existence of methoxy group was  
311 further proved by the appearing signals at  $\delta$  172.00 and  $\delta$  172.05, which prompting partial  
312 GalpA residues might exist methyl ester. Furthermore, signals at  $\delta$  54.13 and  $\delta$  54.20 indicated  
313 that methoxy group was attached to the C-6 position of 1, 4-linked  $\alpha$ -6MeGalpA. Signals at  
314  $\delta$  93.52 and  $\delta$  97.49 might be attributed to anomeric carbon of 4-linked  $\alpha$ -GalpA and 4-linked  
315  $\beta$ -GalpA, respectively. In HSQC (**Fig. 2B**) spectrum, signals at  $\delta$  4.71/97.49 and  $\delta$  5.40/93.52

316 suggested the correlations of anomeric carbon and hydrogen of 4-linked GalpA (**i**, **h**), which  
317 indicating that 4-linked GalpA residues are  $\beta$ - and  $\alpha$ -configuration, respectively. C-1 signal of  
318 T-linked  $\beta$ -Galp (**g**) was overlapped by C-1 signal of 1, 3-linked  $\beta$ -Galp (**f**) and assigned to  $\delta$   
319 104.67. Resonance at  $\delta$  100.25 could be assigned to C1 of 1, 2, 4-linked  $\alpha$ -Rhap (**c**) and its  
320 correlation with H1 of this residue at  $\delta$  5.15 in HSQC spectrum (**Fig. 2B**). Arabian residues  
321 were too weak to be directly observed in  $^{13}\text{C}$  NMR spectrum. However, combined with the  
322 cross peaks at higher chemical shift in HSQC spectrum (**Fig. 2B**), resonances at  $\delta$  5.28/108.18  
323 and  $\delta$  5.17/108.61 could be easily assigned to H1 and C1 of T-linked  $\alpha$ -Araf (**a**) and 1, 5-linked  
324  $\alpha$ -Araf (**b**), respectively. From C-2 to C-6 regions, the strong signals at  $\delta$  69.11,  $\delta$  79.89 and  $\delta$   
325 71.83 were allocated to atoms C-2, C-4 and C-5 of residue **d** (1, 4-linked  $\alpha$ -GalpA), respectively.  
326 Resonances at  $\delta$  69.22,  $\delta$  79.44 and  $\delta$  71.94 were assigned to atoms C-2, C-4 and C-5 of residue  
327 **d'** (1, 4-linked  $\alpha$ -GalpA), respectively. Signals at  $\delta$  71.81 and  $\delta$  83.30 were assigned to atoms  
328 C-2 and C-4 of residues **e** (1, 4-linked  $\alpha$ -6MeOGalpA) and **e'** (1, 4-linked  $\alpha$ -6MeOGalpA) in  
329 different chemical environments, respectively. Signal at  $\delta$  80.27 could belong to C-3 of residue  
330 **f** (1, 3-linked  $\beta$ -Galp). In  $^1\text{H}$  NMR (**Fig. 1A**) spectrum of 922211, the anomeric hydrogens at  $\delta$   
331 5.15 of **c** (1, 2, 4-linked  $\alpha$ -Rhap), **d** (1, 4-linked  $\alpha$ -GalpA) and **d'** (1, 4-linked  $\alpha$ -GalpA) were  
332 overlapped heavily. Signals at  $\delta$  5.01 could be assigned to H1 of **e** (1, 4-linked  $\alpha$ -6MeOGalpA)  
333 and **e'** (1, 4-linked  $\alpha$ -6MeOGalpA). Signals at  $\delta$  4.70 originated from H-1 of **g** (T-linked  $\beta$ -Galp)  
334 and **f** (1, 3-linked  $\beta$ -Galp), respectively. Resonance at  $\delta$  4.71 originated from H-1 of and **i** (4-  
335 linked  $\beta$ -GalpA).


336 Resonance at  $\delta$  5.40 could be assigned to H-1 of **h** (4-linked  $\alpha$ -GalpA). Signals at  $\delta$  5.28  
337 and  $\delta$  5.17 could be assigned to H-1 of **a** (T-linked  $\alpha$ -Araf) and **b** (1, 5-linked  $\alpha$ -Araf),



338 respectively. Comparing with 922211, the resonances belonging to T-, 1, 3-linked Gal and T-,  
 339 1, 5-linked Ara almost vanished in HSQC of P2922211I (**Fig. 1C**). Hence, it might be deduced  
 340 that those vanished glycosyl residues are on side chains.



341  
 342 **Fig. 1.**  $^{13}\text{C}$  NMR spectra of the polysaccharide 922211 and its degraded polysaccharide  
 343 P2922211I A:  $^{13}\text{C}$  NMR spectrum of 922211; B:  $^1\text{H}$  NMR spectrum of 922211; C:  $^{13}\text{C}$  NMR  
 344 spectrum of P2922211I (**a.** T-linked a-Araf; **b.** 1,5 -linked a-Araf; **c.** 1, 2, 4-linked a-Rhap; **d/d'**  
 345 1, 4-linked a-GalpA; **e/e'**. 1, 4-linked  $\alpha$ -6MeOGalpA; **f.** 1, 3-linked  $\beta$ -Galp; **g.** T-linked  $\beta$ -Galp;  
 346 **h.** 4-linked a-GalpA; **i.** 4-linked  $\beta$ -GalpA; **j.** 1, 2-linked a-Rhap).




348

349 **Fig. 2.** COSY (A) and HSQC (B) spectra of 922211 (**a.** T-linked  $\alpha$ -Araf; **b.** 1,5 -linked  $\alpha$ -Araf;  
350 **c.** 1, 2, 4-linked  $\alpha$ -Rhap; **d/d'**. 1, 4-linked  $\alpha$ -GalpA; **e/e'**. 1, 4-linked  $\alpha$ -6MeOGalpA; **f.** 1, 3-  
351 linked  $\beta$ -Galp; **g.** T-linked  $\beta$ -Galp; **h.** 4-linked  $\alpha$ -GalpA; **i.** 4-linked  $\beta$ -GalpA; **j.** 1, 2-linked  $\alpha$ -  
352 Rhap).

353 In HMBC spectrum (**Fig. 3**), strong resonance at  $\delta$  5.15/79.89 indicated that the H-1 of **d**  
354 (1, 4-linked  $\alpha$ -GalpA) was correlated with next C-4 of **d** (1, 4-linked  $\alpha$ -GalpA). Meanwhile, the  
355 correlation at  $\delta$  100.85/4.52 suggested that the C-1 of **d** (1, 4-linked  $\alpha$ -GalpA) was correlated  
356 with next H-4 of **d** (1, 4-linked  $\alpha$ -GalpA). Hence, 1, 4-linked  $\alpha$ -GalpA residues are adjacent to  
357 each other. The cross peaks at  $\delta$  5.15/83.30 and  $\delta$  100.85/4.49 indicated that the H-1 of **d/d'** (1,  
358 4-linked  $\alpha$ -GalpA/another 1, 4-linked  $\alpha$ -GalpA) was correlated with C-4 of **e/e'** (1, 4-linked  $\alpha$ -  
359 6MeOGalpA/another 1, 4-linked  $\alpha$ -6MeOGalpA) and the C-1 of **d** (1, 4-linked  $\alpha$ -GalpA) was  
360 correlated with H-4 of **e'** (1, 4-linked  $\alpha$ -6MeOGalpA), respectively. The resonances at  $\delta$   
361 4.52/101.67 and  $\delta$  79.89/5.01 showed that the H-4 of **d/d'** (1, 4-linked  $\alpha$ -GalpA/ another 1, 4-  
362 linked  $\alpha$ -GalpA) was coupled with C-1 of **e** (1, 4-linked  $\alpha$ -6MeOGalpA) and the C-4 of **d** (1,  
363 4-linked  $\alpha$ -GalpA) was allocated with H-1 of **e/e'** (1, 4-linked  $\alpha$ -6MeOGalpA/1, 4-linked  $\alpha$ -  
364 6MeOGalpA), respectively. Cross peaks at  $\delta$  5.15/78.97 and  $\delta$  100.85/4.20 showed the  
365 correlation between H-1 of **d/d'** (1, 4-linked  $\alpha$ -GalpA/another 1, 4-linked  $\alpha$ -GalpA) and C-2 of  
366 **c** (1, 2, 4-linked  $\alpha$ -Rhap) and association between C-1 of **d** (1, 4-linked  $\alpha$ -GalpA) and H-2 of **c**  
367 (1, 2, 4-linked  $\alpha$ -Rhap). Cross peaks at  $\delta$  5.15/78.89 and  $\delta$  101.08/4.09 suggested the correlation  
368 between H-1 of **d/d'** (1, 4-linked  $\alpha$ -GalpA/another 1, 4-linked  $\alpha$ -GalpA) and C-4 of **c** (1, 2, 4-  
369 linked  $\alpha$ -Rhap) and coupling between C-1 of **d'** (1, 4-linked  $\alpha$ -GalpA) and H-4 of **c** (1, 2, 4-  
370 linked  $\alpha$ -Rhap). Cross peak at  $\delta$  5.15/79.89/79.44 suggested the correlation between H-1 of **c**  
371 (1, 2, 4-linked  $\alpha$ -Rhap) was correlated with C-4 of **d/d'** (1, 4-linked  $\alpha$ -GalpA/another 1, 4-

---

372 linked  $\alpha$ -GalpA). Cross peak at  $\delta$  100.25/4.52 suggested the allocation between C-1 of **c** (1, 2,  
373 4-linked  $\alpha$ -Rhap) and H-4 of **d/d'** (1, 4-linked  $\alpha$ -GalpA/another 1, 4-linked  $\alpha$ -GalpA). The  
374 resonances at  $\delta$  5.15/79.29 and  $\delta$  100.25/4.53 showed that the H-1 of **c** (1, 2, 4-linked  $\alpha$ -Rhap)  
375 was correlated with C-4 of **h** (4-linked  $\alpha$ -GalpA) and the C-1 of **c** (1, 2, 4-linked  $\alpha$ -Rhap) was  
376 associated with H-4 of **h** (4-linked  $\alpha$ -GalpA), respectively. Cross peaks at  $\delta$  5.15/78.74 and  $\delta$   
377 100.25/4.47 suggested the correlation between H-1 of **c** (1, 2, 4-linked  $\alpha$ -Rhap) was correlated  
378 with C-4 of **i** (4-linked  $\beta$ -GalpA) and the C-1 of **c** (1, 2, 4-linked  $\alpha$ -Rhap) was coupled with H-  
379 4 of **i** (4-linked  $\beta$ -GalpA), respectively. Cross peak at  $\delta$  5.17/78.89 suggested the correlation  
380 between H-1 of **b** (1, 5-linked  $\alpha$ -Araf) was allocated with C-4 of **c** (1, 2, 4-linked  $\alpha$ -Rhap). Cross  
381 peak at  $\delta$  5.28/69.84 suggested the correlation between H-1 of **a** (T-linked  $\alpha$ -Araf) was  
382 correlated with adjacent C-5 of **b** (1, 5-linked  $\alpha$ -Araf). Cross peak at  $\delta$  4.70/78.89 suggested the  
383 correlation between H-1 of **f** (1, 3-linked  $\beta$ -Galp) was correlated with C-4 of **c** (1, 2, 4-linked  
384  $\alpha$ -Rhap). Cross peaks at  $\delta$  4.70/80.27 and  $\delta$  104.67/3.73 suggested the correlation between H-1  
385 of **g** (T-linked  $\beta$ -Galp) was correlated with C-3 of **f** (1, 3-linked  $\beta$ -Galp) and the C-1 of **g** (T-  
386 linked  $\beta$ -Galp) was correlated with H-3 of **f** (1, 3-linked  $\beta$ -Galp), respectively. Cross peak at  $\delta$   
387 5.28/78.89 suggested the correlation between H-1 of **a** (T-linked  $\alpha$ -Araf) was correlated with  
388 C-4 of **c** (1, 2, 4-linked  $\alpha$ -Rhap).




389

390 **Fig. 3.** HMBC spectrum of 922211 (**a.** T-linked  $\alpha$ -Araf; **b.** 1,5 -linked  $\alpha$ -Araf; **c.** 1, 2, 4-linked  
391  $\alpha$ -Rhap; **d/d'.** 1, 4-linked  $\alpha$ -GalpA; **e/e'.** 1, 4-linked  $\alpha$ -6MeOGalpA; **f.** 1, 3-linked  $\beta$ -Galp; **g.** T-  
392 linked  $\beta$ -Galp; **h.** 4-linked  $\alpha$ -GalpA; **i.** 4-linked  $\beta$ -GalpA).

393

Combined with the result mentioned above, the intra-dialysate P2922211I contained 1, 4-  
394 linked  $\alpha$ -GalpA and 1, 2-linked  $\alpha$ -Rhap in the molar ratio of 16.71 : 1.00 (47.12 : 2.82 in **table**  
395 **2**). However, linkage type analysis of the native polysaccharide 922211 showed that it contained  
396 1, 4-linked  $\alpha$ -GalpA and 1, 2, 4-linked  $\alpha$ -Rhap in the molar ratio of 37.91 : 6.40. Based on the  
397 huge different proportion of 1, 4-linked  $\alpha$ -GalpA and 1, 2-linked  $\alpha$ -Rhap or 1, 2, 4-linked  $\alpha$ -  
398 Rhap in P2922211I and 922211, it was reasonably deduced that the backbone consisted of two  
399 segments: linear homogalacturonan chains which might be partly methyl esterified and RG I-  
400 type-like fragment bearing 1, 4-linked  $\alpha$ -GalpA, 1, 4-linked  $\alpha$ -GalpAOME and 1, 2, 4-linked  $\alpha$ -  
401 Rhap. There are four branches attached to C-1 or C4 position of Rhamnose glycosyl residues  
402 on backbone. Hence, taken together, the proposed repeating unit of 922211 was presented as

403 following:




406 **Scheme 1.** Schematic structure of 922211.

407 **3.5. Crude polysaccharide 922 was a potent inhibitor of SARS-COV-2 3CLpro**

408 As early as in the study of coronavirus it was found that 3CL protein was an attractive  
409 target molecule against coronavirus. This is because the functional polypeptides are released  
410 from the polyproteins by extensive proteolytic processing during coronavirus complex  
411 replication. This is primarily achieved by the 33.1-kD HCoV 229E main proteinase (Mpro),  
412 which is frequently also called 3C-like proteinase (3CLpro) (Anand et al., 2003). Since the  
413 outbreak of COVID-19 in 2019, with the in-depth study of COVID-19, scientists have also  
414 found that inhibiting the activity of 3CL protein and disturbing the interaction between SARS-  
415 CoV-2-S1 and ACE2 are two feasible strategies for the development the drugs and vaccines in  
416 COVID-19. Hence, some compounds like flavonols, Genkwanine, and Luteolin-glucoside have  
417 high affinity with ACE2 and 3CLpro (Mouffouk et al., 2021; Nouadi et al., 2021). Indeed, some  
418 of their SARS-CoV-2 antiviral effects had also been proved (Mouffouk et al., 2021). Moreover,  
419 it was reported that macromolecular carbohydrate such as heparin might block SARS-CoV-2  
420 binding and infection because negatively charged sulfate and carboxyl groups on heparin could  
421 stabilized the association with several positively charged amino acid residues of spike protein  
422 (Batiha et al., 2020). Our recent study one crude polysaccharide 375 in which contain alginate  
423 might potentially inhibit SARS-CoV-2 virus replication (Zhang et al., 2021). As we know alginate  
424 has  $\beta$ -D-mannuronate (M) and 1, 4-linked  $\alpha$ -L-guluronate. This also suggests that polysaccharide

424 contains uronic acid group may benefit the effect against the virus. However, the most common  
425 type of pectic polysaccharides, with a large carboxyl group, has not been reported on COVID-  
426 19 yet. Therefore, in this study, a polysaccharide containing a large amount of uronic acid was  
427 chosen to screen its activity of inhibiting 3CL protein. Based on the basic characteristics that  
428 2019-nCoV 3CLpro protein is a proteolytic enzyme, a screening system for fluorescence  
429 detection of 2019-nCoV 3CLpro protein activity was established. 2019-nCoV 3CLpro protein  
430 can specifically shear the substrate with GLN (q) at P1 position. Fluorescent polypeptide can  
431 be used as the substrate for its activity detection, and the activity of 3CLpro protein hydrolase  
432 can be reflected by detecting the generation of fluorescent signal. Then the competitive binding  
433 test targeting 3CLpro was examined. The results showed that the crude 922 and the  
434 homogeneous polysaccharide 922211, derived from 922, might potently inhibit SARS-CoV-2  
435 3CLpro activity (**Fig. 4A and B**). Further, the fluorescence resonance energy transfer (FRET)  
436 based cleavage assay was employed to determine the median inhibitory concentration ( $IC_{50}$ )  
437 values. The results revealed good inhibitory potency of 922 and 922211, with  $IC_{50}$  values of  
438  $4.73 \pm 1.05 \mu\text{M}$  and  $0.18 \pm 0.01 \mu\text{M}$  (**Fig. 4A and B**), respectively. The above results imply that  
439 polysaccharide, as the main component of 922 and 922211, might have a blocking effect on  
440 SARS-CoV-2 replication and infection. This inspires us to furtherly explore polysaccharides  
441 against SARS-Cov-2 and their underlying mechanism.



442

443 **Fig. 4.** 922 and 922211 inhibit the activity of SARS-CoV-2 3CL<sup>pro</sup> (A, B); Competitive  
444 intervention of polysaccharide 922 on S1 protein and ACE2 (C). The protease activity of SARS-  
445 CoV-2 3CL<sup>pro</sup> was measured in the presence of increasing concentrations of the 922 and  
446 922211, SARS-CoV-2 3CL<sup>pro</sup> preincubated for 20 min with each concentration of 922 and  
447 922211. The protease activity was measured by the FRET-based protease assay. Dose–response  
448 curves for IC<sub>50</sub> values were determined by nonlinear regression. All data are shown as mean ±  
449 SD. n = 3 biological replicates (A, B). Competitive intervention of crude polysaccharide 922  
450 and Clioquinol with concentrations of 5 μM and 20 μM on S1 protein and ACE2 interaction by  
451 ELISA experiment (C). Final concentrations of ACE2 and biotinylated -S1 protein were 2  
452 μg/mL and 500 ng/mL, respectively.

453 *3.6. 922 may disturb the interaction between SARS-CoV-2-S1 and ACE2*


454 The spike protein of SARS-CoV-2 shows more than 90% amino acid similarity to that of  
455 pangolin and bat CoVs which also bind to human angiotensin-convert enzyme 2 (ACE2) for  
456 the virus infection. Thus, S protein is very vital for viral invasion. Interestingly, unoccupied  
457 glycosylation sites on SARS-CoV-2 S and the glycan binding site of N-terminal domain of S1



458 protein imply S protein may bind with carbohydrate (Kirchdoerfer et al., 2016; Watanabe et al.,  
459 2020). To further screen the bioactivity of 922 and 922211 against SARS-Cov-2, ELISA was  
460 used to examine whether 922 and 922211 might disturb the binding between S1 protein *in vitro*.  
461 The results showed that polysaccharide 922 could impede weakly the binding of S1 protein  
462 with ACE2 (**Fig. 4C**). These results also suggest that anti-SARS-CoV-2 effects of 922 and  
463 922211 are more likely to inhibit 3CL protein activity than disturbing the interaction between  
464 SARS-CoV-2-S1 and ACE2.

### 465 3.7. 922 exhibit anti-viral effect on SARS-CoV-2

466 The above results implied that 922 might have potential inhibitory effect on SARS-Cov-  
467 2. Hence, the inhibition effect of native polysaccharide 922 against the virus was examined.  
468 Surprisingly, polysaccharide 922 nearly completely blocked SARS-Cov-2 replication *in vitro*,  
469 exhibiting very good anti-SARS-CoV-2 activity in Vero E6 cells. The inhibition rate was 99.9%  
470 (**Fig. 5A**). The EC<sub>50</sub> value was 0.90  $\mu$ M (or 5.01  $\mu$ g/mL) (**Fig. 5B**). The above results suggested  
471 that 922 is the good candidate for anti-SARS-Cov-2 new drug development. Following, we will  
472 further explore the antiviral mechanism for 922 and 922211.



473  
474 **Fig. 5.** *in vitro* inhibition of polysaccharides against SARS-CoV-2. (A) viral RNA copy number  
475 was detected by qPCR after the treatment of solvent (H<sub>2</sub>O) control, Remdesivir positive control  
476 (10  $\mu$ M), crude polysaccharide 922 in 20  $\mu$ g/mL and 200  $\mu$ g/mL, respectively. (B) EC<sub>50</sub> of crude

---

477 polysaccharide 922 against SARS-CoV-2.

478


## 479 **Discussion**

480 In this study, we uncovered for the first time that polysaccharide and a novel pectin  
481 extracted from traditional Chinese medicine *Syzygium aromaticum* flower inhibited strongly  
482 the replication of SARS-CoV-2, and the inhibition rate was 99.9%. Further study showed that  
483 922 and 922211 might competitively bind to SARS-CoV-2 key enzyme 3CLpro. The  
484 experimental results evidenced our hypothesis that acidic polysaccharides such as pectin might  
485 have anti-SARS-CoV-2 effect. In the current anti-virus investigations of polysaccharides,  
486 heparin (Gupta et al., 2021; Tandon et al., 2021) or polysaccharides extracted from seaweed  
487 (Rosales-Mendoza et al., 2020), alginate (Zhang et al., 2021), with large amounts of sulfate ions  
488 and chitosan derivatives (Modak et al., 2021) have been studied. Moreover, the chitosan  
489 derivatives are also sulfated chitosan, which has significant or potent effect on anti-SARS-CoV-  
490 2. Unlike other sulfated polysaccharides, which antiviral activity is mainly arisen from  
491 competitive inhibition of S1 and ACE2 binding, both 922 and the pectin-like glycan 922211  
492 might impede 3CLpro activity, but only tenderly disturb the binding of S1 and ACE2.

493 To further understand whether there some other components in the 922 may interfere  
494 3CLpro, PLpro, or RdRp enzyme activity. We firstly pooled the fragment from 922 crude  
495 polysaccharide eluted by distilled water, 0.05 M NaCl, 0.1 M NaCl, 0.2 M NaCl, 0.4 M NaCl,  
496 stepwise to achieve 9220S, 9220P, 92205S, 92205P, 9221S, 9221P, 9222S, 9222P, 9224S, and  
497 9224P, respectively (**Fig. 6F**). Then all of those fragments were employed to test their effects  
498 on 3CLpro, PLpro and RdRp enzymes activities. Interestingly, 9220P, 9221P, 9222P, 9224P,  
499 9221S might significantly impede 3CLpro activity (**Fig. 6A-E**). The IC<sub>50</sub> of 9220P, 9221P,

500 9222P, 9224P, 9221S on 3CLpro was roughly 76.57  $\mu\text{g/mL}$ , 42.12  $\mu\text{g/mL}$ , 17.17  $\mu\text{g/mL}$ , 14.36  
501  $\mu\text{g/mL}$ , 22.99  $\mu\text{g/mL}$  (**Fig. 6A-E**), respectively. Surprisingly, 92205P, 9222P and 9224P could  
502 also potently inhibit RdRp enzyme activity, while 9222P and 9224P might nearly completely  
503 block this enzyme activity (**Table S1**). However, almost all of these components have no  
504 significant effect on the PLpro enzyme (**Table S1**). This imply that polysaccharide 922 inhibit  
505 SARS-CoV-2 virus replication at least through disturbing both 3CLpro and RdRp enzymes, but  
506 has nothing to do with PLpro enzyme.

507         Although the detail mechanism underlying the action of 922 and 922211 need to be further  
508 explored, our study provides evidences for the first time for pectin or pectin-like polysaccharide  
509 might be promising candidate for the anti-SARS-CoV-2 virus new drug development.



510

511 **Fig. 6.** 9221S, 9220P, 9221P, 9222P and 9224P inhibit the activity of SARS-Cov-2 3CLpro (A-

512 E). Schematic diagram of 922 separation, purification. 922 and fractions arising from it

513 determinate enzymatic activity and inhibition assays of SARS-CoV-2 3CLpro, PLpro and RdRp

514 (F). The protease activity of SARS-CoV-2 3CLpro was measured in the presence of increasing

515 concentrations of the 9221S, 9220P, 9221P, 9222P and 9224P, SARS-CoV-2 3CLpro

516 preincubated for 20 min with each concentration of above five samples, the protease activity

517 was measured by the FRET-based protease assay. Dose–response curves for IC<sub>50</sub> values were  
518 determined by nonlinear regression. All data are shown as mean ± SD. n = 3 biological  
519 replicates. (9220P: the fraction from 922 mainly containing protein separated by DEAE  
520 Sepharose Fast Flow (anion-exchange chromatography, eluted by distill water); 9220S: the  
521 fraction from 922 mainly containing sugar separated by DEAE Sepharose Fast Flow, eluted by  
522 distill water; 92205P: the fraction from 922 mainly containing protein separated by DEAE  
523 Sepharose Fast Flow, eluted by 0.05 M NaCl; 92205S: the fraction from 922 mainly containing  
524 sugar separated by DEAE Sepharose Fast Flow, eluted by 0.05 M NaCl; 9221P: the fraction  
525 from 922 mainly containing protein separated by DEAE Sepharose Fast Flow, eluted by 0.1 M  
526 NaCl; 9221S: the fraction from 922 mainly containing sugar separated by DEAE Sepharose  
527 Fast Flow, eluted by 0.1 M NaCl; 9222P: the fraction from 922 mainly containing protein  
528 separated by DEAE Sepharose Fast Flow, eluted by 0.2 M NaCl; 9222S: the fraction from 922  
529 mainly containing sugar separated by DEAE Sepharose Fast Flow, eluted by 0.2 M NaCl;  
530 9224P: the fraction from 922 mainly containing protein separated by DEAE Sepharose Fast  
531 Flow, eluted by 0.4 M NaCl; 9224S: the fraction from 922 mainly containing sugar separated  
532 by DEAE Sepharose Fast Flow, eluted by 0.4 M NaCl; 9222111: the homogenous  
533 polysaccharide from 9222S purified by Sephacryl S-100 HR (gel permeation chromatography);  
534 922111: the polysaccharide from 9221S purified by Sephacryl S-100 HR).

535

### 536 **Acknowledgment**

537 This work was supported by Shanghai Municipal Science and Technology Major Project,  
538 Key New Drug Creation and Manufacturing Program (Grant number 2019ZX09735001),

539 National Key R&D Program, Ministry of Science and Technology of China (Grant number  
540 2019YFC1711-000), COVID-19 Emergency Research Project founded by Zhejiang University  
541 (2020XGZX080). We are particularly grateful to Tao Du and Lun Wang from Zhengdian  
542 Biosafety Level 3 Laboratory and the running team of the laboratory for their work

543

#### 544 **References**

545 Anand, K., Ziebuhr, J., Wadhvani, P., Mesters, J. R., & Hilgenfeld, R. (2003). Coronavirus  
546 main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. *Science (New York,*  
547 *N.Y.), 300*(5626), 1763–1767. <https://doi.org/10.1126/science.1085658>

548 Arvin, A. M., Fink, K., Schmid, M. A., Cathcart, A., Spreafico, R., Havenar-Daughton, C.,  
549 Lanzavecchia, A., Corti, D., & Virgin, H. W. (2020). A perspective on potential antibody-  
550 dependent enhancement of SARS-CoV-2. *Nature, 584*(7821), 353–363.  
551 <https://doi.org/10.1038/s41586-020-2538-8>

552 Asselah, T., Durantel, D., Pasmant, E., Lau, G., & Schinazi, R. F. (2021). COVID-19:  
553 Discovery, diagnostics and drug development. *Journal of Hepatology, 74*(1), 168–184.  
554 <https://doi.org/10.1016/j.jhep.2020.09.031>

555 Báez-Santos, Y. M., St John, S. E., & Mesecar, A. D. (2015). The SARS-coronavirus papain-  
556 like protease: structure, function and inhibition by designed antiviral compounds. *Antiviral*  
557 *Research, 115*, 21–38. <https://doi.org/10.1016/j.antiviral.2014.12.015>

558 Batiha, G. E.-S., Alkazmi, L. M., Wasef, L. G., Beshbishy, A. M., Nadwa, E. H., & Rashwan,  
559 E. K. (2020). *Syzygium aromaticum* L. (Myrtaceae): Traditional Uses, Bioactive Chemical  
560 Constituents, Pharmacological and Toxicological Activities. *Biomolecules, 10*(2), 202.

- 561 <https://doi.org/10.3390/biom10020202>
- 562 Batiha, G. E.-S., Beshbishy, A. M., Tayebwa, D. S., Shaheen, H. M., Yokoyama, N., & Igarashi,  
563 I. (2019). Inhibitory effects of *Syzygium aromaticum* and *Camellia sinensis* methanolic extracts  
564 on the growth of *Babesia* and *Theileria* parasites. *Ticks and Tick-Borne Diseases*, *10*(5), 949–  
565 958. <https://doi.org/10.1016/j.ttbdis.2019.04.016>
- 566 Chen, R.-R., Li, Y.-J., Chen, J.-J., & Lu, C.-L. (2020). A review for natural polysaccharides  
567 with anti-pulmonary fibrosis properties, which may benefit to patients infected by 2019-nCoV.  
568 *Carbohydrate Polymers*, *247*, 116740. <https://doi.org/10.1016/j.carbpol.2020.116740>
- 569 Cong, Q., Shang, M., Dong, Q., Liao, W., Xiao, F., & Ding, K. (2014). Structure and activities  
570 of a novel heteroxylan from *Cassia obtusifolia* seeds and its sulfated derivative. *Carbohydrate*  
571 *Research*, *393*, 43–50. <https://doi.org/10.1016/j.carres.2014.04.016>
- 572 Cucinotta, D., & Vanelli, M. (2020). WHO Declares COVID-19 a Pandemic. *Acta Bio-Medica* :  
573 *Atenei Parmensis*, *91*(1), 157–160. <https://doi.org/10.23750/abm.v91i1.9397>
- 574 Dai, J., Wu, Y., Chen, S. W., Zhu, S., Yin, H. P., Wang, M., & Tang, J. (2010). Sugar  
575 compositional determination of polysaccharides from *Dunaliella salina* by modified RP-HPLC  
576 method of precolumn derivatization with 1-phenyl-3-methyl-5-pyrazolone. *Carbohydrate*  
577 *Polymers*, *82*(3), 629–635. <https://doi.org/10.1016/j.carbpol.2010.05.029>
- 578 Dai, W., Zhang, B., Jiang, X.-M., Su, H., Li, J., Zhao, Y., Xie, X., Jin, Z., Peng, J., Liu, F., Li,  
579 C., Li, Y., Bai, F., Wang, H., Cheng, X., Cen, X., Hu, S., Yang, X., Wang, J., & Liu, H. (2020).  
580 Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.  
581 *Science (New York, N.Y.)*, *368*(6497), 1331–1335. <https://doi.org/10.1126/science.abb4489>
- 582 Dong, Q., Liu, X., Yao, J., Dong, X., Ma, C., Xu, Y., Fang, J., & Ding, K. (2010). Structural

583 characterization of a pectic polysaccharide from *Nerium indicum* flowers. *Phytochemistry*,  
584 *71*(11–12), 1430–1437. <https://doi.org/10.1016/j.phytochem.2010.05.019>

585 Froggatt, H. M., Heaton, B. E., & Heaton, N. S. (2020). Development of a Fluorescence-Based,  
586 High-Throughput SARS-CoV-2 3CL(pro) Reporter Assay. *Journal of Virology*, *94*(22),  
587 e01265-20. <https://doi.org/10.1128/JVI.01265-20>

588 Golovchenko, V. V, Bushneva, O. A., Ovodova, R. G., Shashkov, A. S., Chizhov, A. S., &  
589 Ovodov, I. S. (2007). Structural study of bergenan, a pectin from *Bergenia crassifolia*.  
590 *Bioorganicheskaia khimiia*, *33*(1), 54–63. <https://doi.org/10.1134/s1068162007010050>

591 Gupta, Y., Maciorowski, D., Zak, S. E., Kulkarni, C. V, Herbert, A. S., Durvasula, R., Fareed,  
592 J., Dye, J. M., & Kempaiah, P. (2021). Heparin: A simplistic repurposing to prevent SARS-  
593 CoV-2 transmission in light of its *in-vitro* nanomolar efficacy. *International Journal of*  
594 *Biological Macromolecules*, *183*, 203–212. <https://doi.org/10.1016/j.ijbiomac.2021.04.148>

595 HAKOMORI, S. (1964). A RAPID PERMETHYLATION OF GLYCOLIPID, AND  
596 POLYSACCHARIDE CATALYZED BY METHYLSULFINYL CARBANION IN  
597 DIMETHYL SULFOXIDE. *Journal of Biochemistry*, *55*, 205–208.

598 Hatmal, M. M., Alshaer, W., Al-Hatamleh, M. A. I., Hatmal, M., Smadi, O., Taha, M. O.,  
599 Oweida, A. J., Boer, J. C., Mohamud, R., & Plebanski, M. (2020). Comprehensive Structural  
600 and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV,  
601 and Their Interactions with ACE2. *Cells*, *9*(12), 2638. <https://doi.org/10.3390/cells9122638>

602 Hu, Y., Meng, X., Zhang, F., Xiang, Y., & Wang, J. (2021). The *in vitro* antiviral activity of  
603 lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting  
604 the heparan sulfate co-receptor. *Emerging Microbes & Infections*, *10*(1), 317–330.



- 
- 605 <https://doi.org/10.1080/22221751.2021.1888660>
- 606 Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C.,  
607 Duan, Y., Yu, J., Wang, L., Yang, K., Liu, F., Jiang, R., Yang, X., You, T., Liu, X., & Yang,  
608 H. (2020). Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. *Nature*,  
609 582(7811), 289–293. <https://doi.org/10.1038/s41586-020-2223-y>
- 610 Kirchdoerfer, R. N., Cottrell, C. A., Wang, N., Pallesen, J., Yassine, H. M., Turner, H. L.,  
611 Corbett, K. S., Graham, B. S., McLellan, J. S., & Ward, A. B. (2016). Pre-fusion structure of a  
612 human coronavirus spike protein. *Nature*, 531(7592), 118–121.  
613 <https://doi.org/10.1038/nature17200>
- 614 Kocabiyik, O., Cagno, V., Silva, P. J., Zhu, Y., Sedano, L., Bhide, Y., Mettier, J., Medaglia, C.,  
615 Da Costa, B., Constant, S., Huang, S., Kaiser, L., Hinrichs, W. L. J., Huckriede, A., Le Goffic,  
616 R., Tapparel, C., & Stellacci, F. (2021). Non-Toxic Virucidal Macromolecules Show High  
617 Efficacy Against Influenza Virus Ex Vivo and In Vivo. *Advanced Science (Weinheim, Baden-*  
618 *Wuerttemberg, Germany)*, 8(3), 2001012. <https://doi.org/10.1002/advs.202001012>
- 619 Laventhal, N., Basak, R., Dell, M. L., Diekema, D., Elster, N., Geis, G., Mercurio, M., Opel,  
620 D., Shalowitz, D., Statter, M., & Macauley, R. (2020). The Ethics of Creating a Resource  
621 Allocation Strategy During the COVID-19 Pandemic. *Pediatrics*, 146(1), e20201243.  
622 <https://doi.org/10.1542/peds.2020-1243>
- 623 Li, S., Li, M., Yue, H., Zhou, L., Huang, L., Du, Z., & Ding, K. (2018). Structural elucidation  
624 of a pectic polysaccharide from *Fructus Mori* and its bioactivity on intestinal bacteria strains.  
625 *Carbohydrate Polymers*, 186, 168–175. <https://doi.org/10.1016/j.carbpol.2018.01.026>
- 626 Lin, L., Wang, P., Du, Z., Wang, W., Cong, Q., Zheng, C., Jin, C., Ding, K., & Shao, C. (2016).

627 Structural elucidation of a pectin from flowers of *Lonicera japonica* and its antipancreatic  
628 cancer activity. *International Journal of Biological Macromolecules*, 88, 130–137.  
629 <https://doi.org/10.1016/j.ijbiomac.2016.03.025>

630 Liu, Q., Fang, J., Wang, P., Du, Z., Li, Y., Wang, S., & Ding, K. (2018). Characterization of a  
631 pectin from *Lonicera japonica* Thunb. and its inhibition effect on A $\beta$ <sub>(42)</sub> aggregation and  
632 promotion of neuritogenesis. *International Journal of Biological Macromolecules*, 107(Pt A),  
633 112–120. <https://doi.org/10.1016/j.ijbiomac.2017.08.154>

634 Majumder, J., & Minko, T. (2021). Recent Developments on Therapeutic and Diagnostic  
635 Approaches for COVID-19. *The AAPS Journal*, 23(1), 14. [https://doi.org/10.1208/s12248-020-](https://doi.org/10.1208/s12248-020-00532-2)  
636 [00532-2](https://doi.org/10.1208/s12248-020-00532-2)

637 Modak, C., Jha, A., Sharma, N., & Kumar, A. (2021). Chitosan derivatives: A suggestive  
638 evaluation for novel inhibitor discovery against wild type and variants of SARS-CoV-2 virus.  
639 *International Journal of Biological Macromolecules*, 187, 492–512.  
640 <https://doi.org/10.1016/j.ijbiomac.2021.07.144>

641 Mouffouk, C., Mouffouk, S., Mouffouk, S., Hambaba, L., & Haba, H. (2021). Flavonols as  
642 potential antiviral drugs targeting SARS-CoV-2 proteases (3CL(pro) and PL(pro)), spike  
643 protein, RNA-dependent RNA polymerase (RdRp) and angiotensin-converting enzyme II  
644 receptor (ACE2). *European Journal of Pharmacology*, 891, 173759.  
645 <https://doi.org/10.1016/j.ejphar.2020.173759>

646 Moustaqil, M., Ollivier, E., Chiu, H.-P., Van Tol, S., Rudolffi-Soto, P., Stevens, C., Bhumkar,  
647 A., Hunter, D. J. B., Freiberg, A. N., Jacques, D., Lee, B., Sierecki, E., & Gambin, Y. (2021).  
648 SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of

649 inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across  
650 species. *Emerging Microbes & Infections*, *10*(1), 178–195.  
651 <https://doi.org/10.1080/22221751.2020.1870414>

652 Muchtaridi, M., Fauzi, M., Khairul Ikram, N. K., Mohd Gazzali, A., & Wahab, H. A. (2020).  
653 Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-  
654 CoV-2. *Molecules (Basel, Switzerland)*, *25*(17), 3980.  
655 <https://doi.org/10.3390/molecules25173980>

656 Nouadi, B., Ezaouine, A., El Messal, M., Blaghen, M., Bennis, F., & Chegiani, F. (2021).  
657 Prediction of Anti-COVID 19 Therapeutic Power of Medicinal Moroccan Plants Using  
658 Molecular Docking. *Bioinformatics and Biology Insights*, *15*, 1-11.  
659 <https://doi.org/10.1177/11779322211009199>

660 Pereira, L., & Critchley, A. T. (2020). The COVID 19 novel coronavirus pandemic 2020:  
661 seaweeds to the rescue? Why does substantial, supporting research about the antiviral properties  
662 of seaweed polysaccharides seem to go unrecognized by the pharmaceutical community in  
663 these desperate times? *Journal of Applied Phycology*, 1–3. [https://doi.org/10.1007/s10811-020-](https://doi.org/10.1007/s10811-020-02143-y)  
664 [02143-y](https://doi.org/10.1007/s10811-020-02143-y)

665 Petersen, B. O., Meier, S., Duus, J. Ø., & Clausen, M. H. (2008). Structural characterization of  
666 homogalacturonan by NMR spectroscopy-assignment of reference compounds. *Carbohydrate*  
667 *Research*, *343*(16), 2830–2833. <https://doi.org/10.1016/j.carres.2008.08.016>

668 Petrosillo, N., Viceconte, G., Ergonul, O., Ippolito, G., & Petersen, E. (2020). COVID-19,  
669 SARS and MERS: are they closely related? *Clinical Microbiology and Infection : The Official*  
670 *Publication of the European Society of Clinical Microbiology and Infectious Diseases*, *26*(6),

- 671 729–734. <https://doi.org/10.1016/j.cmi.2020.03.026>
- 672 Radünz, M., da Trindade, M. L. M., Camargo, T. M., Radünz, A. L., Borges, C. D., Gandra, E.  
673 A., & Helbig, E. (2019). Antimicrobial and antioxidant activity of unencapsulated and  
674 encapsulated clove (*Syzygium aromaticum* L.) essential oil. *Food Chemistry*, 276, 180–186.  
675 <https://doi.org/10.1016/j.foodchem.2018.09.173>
- 676 Rosales-Mendoza, S., García-Silva, I., González-Ortega, O., Sandoval-Vargas, J. M., Malla, A.,  
677 & Vimolmangkang, S. (2020). The Potential of Algal Biotechnology to Produce Antiviral  
678 Compounds and Biopharmaceuticals. *Molecules (Basel, Switzerland)*, 25(18), 4049.  
679 <https://doi.org/10.3390/molecules25184049>
- 680 Russo, M., Moccia, S., Spagnuolo, C., Tedesco, I., & Russo, G. L. (2020). Roles of flavonoids  
681 against coronavirus infection. *Chemico-Biological Interactions*, 328, 109211.  
682 <https://doi.org/10.1016/j.cbi.2020.109211>
- 683 Shakhmatov, E. G., Udoratina, E. V, Atukmaev, K. V, & Makarova, E. N. (2015). Extraction  
684 and structural characteristics of pectic polysaccharides from *Abies sibirica* L. *Carbohydrate  
685 Polymers*, 123, 228–236. <https://doi.org/10.1016/j.carbpol.2015.01.041>
- 686 Tandon, R., Sharp, J. S., Zhang, F., Pomin, V. H., Ashpole, N. M., Mitra, D., McCandless, M.  
687 G., Jin, W., Liu, H., Sharma, P., & Linhardt, R. J. (2021). Effective Inhibition of SARS-CoV-  
688 2 Entry by Heparin and Enoxaparin Derivatives. *Journal of Virology*, 95(3), e01987-20.  
689 <https://doi.org/10.1128/JVI.01987-20>
- 690 Taylor, R. L., & Conrad, H. E. (1972). Stoichiometric depolymerization of polyuronides and  
691 glycosaminoglycuronans to monosaccharides following reduction of their carbodiimide-  
692 activated carboxyl groups. *Biochemistry*, 11(8), 1383–1388.

- 
- 693 <https://doi.org/10.1021/bi00758a009>
- 694 Watanabe, Y., Allen, J. D., Wrapp, D., McLellan, J. S., & Crispin, M. (2020). Site-specific  
695 glycan analysis of the SARS-CoV-2 spike. *Science (New York, N.Y.)*, *369*(6501), 330–333.  
696 <https://doi.org/10.1126/science.abb9983>
- 697 Yadav, R., Chaudhary, J. K., Jain, N., Chaudhary, P. K., Khanra, S., Dhamija, P., Sharma, A.,  
698 Kumar, A., & Handu, S. (2021). Role of Structural and Non-Structural Proteins and Therapeutic  
699 Targets of SARS-CoV-2 for COVID-19. *Cells*, *10*(4), 821.  
700 <https://doi.org/10.3390/cells10040821>
- 701 Yan, F., & Gao, F. (2021). An overview of potential inhibitors targeting non-structural proteins  
702 3 (PL(pro) and Mac1) and 5 (3CL(pro)/M(pro)) of SARS-CoV-2. *Computational and*  
703 *Structural Biotechnology Journal*, *19*, 4868–4883. <https://doi.org/10.1016/j.csbj.2021.08.036>
- 704 Yeung, M. L., Teng, J. L. L., Jia, L., Zhang, C., Huang, C., Cai, J.-P., Zhou, R., Chan, K.-H.,  
705 Zhao, H., Zhu, L., Siu, K.-L., Fung, S.-Y., Yung, S., Chan, T. M., To, K. K.-W., Chan, J. F.-  
706 W., Cai, Z., Lau, S. K. P., Chen, Z., & Yuen, K.-Y. (2021). Soluble ACE2-mediated cell entry  
707 of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system. *Cell*,  
708 *184*(8), 2212–2228.e12. <https://doi.org/10.1016/j.cell.2021.02.053>
- 709 Zhang, S., Pei, R., Li, M., Sun, H., Su, M., Ding, Y., Chen, X., Du, Z., Jin, C., Huang, C., Zang,  
710 Y., Li, J., Xu, Y., Chen, X., Zhang, B., & Ding, K. (2021). Structural characterization of  
711 cocktail-like targeting polysaccharides from *Ecklonia kurome* Okam and their anti-SARS-CoV-  
712 2 activities *in vitro*. *BioRxiv*, May. <https://doi.org/10.1101/2021.01.14.426521>
- 713 Zheng, C., Dong, Q., Chen, H., Cong, Q., & Ding, K. (2015). Structural characterization of a  
714 polysaccharide from *Chrysanthemum morifolium* flowers and its antioxidant activity.

715 *Carbohydrate Polymers*, 130, 113–121. <https://doi.org/10.1016/j.carbpol.2015.05.004>

716